ciprofloxacin has been researched along with celecoxib in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Kalle, AM; Rizvi, A | 1 |
| Brincat, JP; Carosati, E; Cecchetti, V; Gosetto, F; Iraci, N; Kaatz, GW; Manfroni, G; Sabatini, S; Serritella, S; Tabarrini, O; Villarini, M | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bernardino, AMR; Boechat, N; Dos Santos, MS; Faria, JV; Miguita, AGC; Vegi, PF | 1 |
| Bishayi, B; Dey, R; Sultana, S | 1 |
| Armstrong, GAB; Goldshtein, H; Muhire, A; Petel Légaré, V; Peterson, RT; Pushett, A; Rotkopf, R; Russek-Blum, N; Shefner, JM | 1 |
| Abramovich, B; Beaulieu, D; Berry, JD; Birman, N; Drory, VE; Eitan, E; Elgrart, K; Ennist, DL; Paganoni, S; Pushett, A; Russek-Blum, N; Salomon-Zimri, S; Shefner, JM; Van Eijk, RPA | 1 |
3 review(s) available for ciprofloxacin and celecoxib
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Recently reported biological activities of pyrazole compounds.
Topics: Analgesics; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antifungal Agents; Antineoplastic Agents; Antiviral Agents; Humans; Pyrazoles | 2017 |
1 trial(s) available for ciprofloxacin and celecoxib
| Article | Year |
|---|---|
Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS.
Topics: Amyotrophic Lateral Sclerosis; Biomarkers; Celecoxib; Ciprofloxacin; COVID-19; Disease Progression; DNA-Binding Proteins; Double-Blind Method; Humans; Neurodegenerative Diseases | 2023 |
6 other study(ies) available for ciprofloxacin and celecoxib
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Inhibition of bacterial multidrug resistance by celecoxib, a cyclooxygenase-2 inhibitor.
Topics: Ampicillin; Celecoxib; Chloramphenicol; Ciprofloxacin; Cyclooxygenase 2 Inhibitors; Drug Resistance, Multiple, Bacterial; Kanamycin; Microbial Sensitivity Tests; Mycobacterium smegmatis; Pyrazoles; Staphylococcus aureus; Sulfonamides | 2011 |
Pyrazolo[4,3-c][1,2]benzothiazines 5,5-dioxide: a promising new class of Staphylococcus aureus NorA efflux pump inhibitors.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Resistance, Multiple, Bacterial; Drug Synergism; Microbial Sensitivity Tests; Models, Molecular; Multidrug Resistance-Associated Proteins; Pyrazoles; Small Molecule Libraries; Staphylococcus aureus; Structure-Activity Relationship; Sulfonamides; Thiazines | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Combination treatment of celecoxib and ciprofloxacin attenuates live S. aureus induced oxidative damage and inflammation in murine microglia via regulation of cytokine balance.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cell Differentiation; Cells, Cultured; Ciprofloxacin; Cytokines; Inflammation; Male; Mice; Microglia; Oxidative Stress; Staphylococcal Infections; Staphylococcus aureus | 2018 |
Efficacy of Ciprofloxacin/Celecoxib combination in zebrafish models of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Animals, Genetically Modified; Celecoxib; Ciprofloxacin; Disease Models, Animal; DNA-Binding Proteins; Motor Neurons; Mutation; Neuromuscular Junction; Superoxide Dismutase; Zebrafish; Zebrafish Proteins | 2020 |